Table 1.
Inducers | Molecular mechanism | TOP1-DPC | TOP2-DPC | References | |
---|---|---|---|---|---|
Anticancer drugs | TOP1 and TOP2 poisons | Interfacial inhibition with a single drug molecule bound at the DNA break-topoisomerase interface |
|
|
[193,194,195,196] |
Platinum salts | DNA distortion | Cisplatin, carboplatin | Unknown | [197] | |
Antimetabolites | DNA distortions; ribonucleotide incorporations | Hydroxyurea, Gemcitabine, Cytarabine, Fluorodeoxyruridine | Unknown | [19,20,160,198,199,200,201,202,203] | |
Others | Distortion of DNA minor groove | Hoechst 33342 Nogalamycin Actinomycin D |
Actinomycin D | [204,205,206,207,208,209] | |
Carcinogens | Food & environmental products | DNA distortions & topoisomerase alterations | Trapping by carcinogenic base damage, exocyclic adducts, crosslinks, benzo[a] pyrene & crotonaldehyde adducts | Trapping by flavone derivatives, tea and wine products & carcinogenic base adducts | [5,203,210,211,212,213,214,215,216,217,218,219,220,221] |
UV adducts & IR-induced DNA damage | DNA distortions, base alterations & breaks | Trapping by DNA alterations | Trapping by DNA alterations and enzymatic inhibition | [222,223,224] [16,17,18,218,225] | |
Endogenous metabolites & DNA alterations | ROS - aldehydes | DNA distortions | DNA alterations | DNA alterations | [215,219,226,227] |
Abasic sites, mismatches, DNA breaks | DNA distortions | DNA distortions | DNA distortions | [16,17,18,19,20,218,219,225,228,229,230] | |
Ribonucleotide incorporation in DNA | Chemical reactivity & DNA distortions | Trapping of flanking TOP1cc | Trapping of TOP2cc | [19,20,160,198,199,200] | |
Transcription | Unknown | Unknown | Enhancers | Promoters | [35,36,37,38,39,40] |
DNA repair defects | Genetic alterations | Lack of TOP-DPC excision | TDP1, SPRTN, RNase H2 and ATM deficiencies | TDP2 deficiency and MRE11 | [23,25,27,35,129,231,232,233,234] |